TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05022199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY fluorescent angiography
Description: This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
Study: NCT04827550

Intervention type: OTHER
Intervention: STUDY
Description: Fibromyalgia Patient

Intervention type: OTHER
Intervention: STUDY
Description: Fibromyalgia Patient
Study: NCT05115240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio-book
Description: Participants listen to an audio book for the same amount of time as the body scan groups
Study: NCT06633159

Intervention type: DEVICE
Intervention: MitraClip
Description: surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets

Intervention type: DEVICE
Intervention: MitraClip
Description: surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
Study: NCT06632808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
Study: NCT06415344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: Antisense Oligonucleotide
Study: NCT05277714

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF
Description: The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level.
Study: NCT05804513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s/c injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s/c injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector
Description: s/c injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector
Description: s/c injection
Study: NCT06112821

Intervention type: OTHER
Intervention: Data collection in medical records
Description: Data collection in medical records

Intervention type: OTHER
Intervention: Data collection in medical records
Description: Data collection in medical records

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
Study: NCT06593457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP
Description: NX-5948 oral
Study: NCT06303089

Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
Study: NCT06593457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP
Description: NX-5948 oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP
Description: NX-5948 oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Fluconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Fluconazole
Study: NCT04919499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765128
Description: BI 765128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765128
Description: BI 765128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765128
Description: BI 765128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765128
Description: BI 765128

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator
Study: NCT06696105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanish XT varnish (resin modified glass ionomer restoration)
Description: Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Study: NCT06699199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine Fluoride 38%
Description: Intervention is the application of Silver diamine fluoride 38% to children Group in arm 1 (Arm 1): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth~SDF: (Silver diamine fluoride 38% is a material used for arresting caries lesions in primary and permanent teeth)~- SDF Product generic name and information (E-SDF: it is a 1-step Technique) - The 38% SDF solution comprised a blend of silver, fluoride, and ammonia at a total concentration of 38%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride- potassium iodide
Description: Intervention is the application of Silver diamine fluoride 38% + potassium iodide to children Group in arm 2 (Arm 2): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth, Followed by an second minute of potassium iodide solution application~- SDF Product generic name and information (Riva-star: it is a 2-step Technique) 30-35% SDF solution (1st step) comprised a blend of silver, fluoride, and ammonia applied in combination with a second application of potassium iodide solution (2nd step)
Study: NCT06699095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.
Study: NCT06699407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishenyiqi dripping pills
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Study: NCT06778967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Administered SC
Study: NCT06778018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lotus Seed
Description: Regimen supplemented with 200 mg/kg of Lotus Seed capsules for 12-month randomized controlled trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Regimen supplemented with 200 mg/kg of Starch capsules for 12-month randomized controlled trial.
Study: NCT06779357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artwork
Description: d. A 3-arm randomized control trial will be used: one arm with Zentangle workshops, the other arm with Pastel Nagomi Art, while the control group will receive usual care. Data collection from each participant will be conducted at 3-time points, at baseline (T0) before the 4-week weekly Pastel Nagomi Art or Zentangle Art program, right after the program (T1), and one month after the program (T2). T

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artwork
Description: d. A 3-arm randomized control trial will be used: one arm with Zentangle workshops, the other arm with Pastel Nagomi Art, while the control group will receive usual care. Data collection from each participant will be conducted at 3-time points, at baseline (T0) before the 4-week weekly Pastel Nagomi Art or Zentangle Art program, right after the program (T1), and one month after the program (T2). T
Study: NCT06777537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talniflumate
Description: Talniflumate was administered
Study: NCT06236841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-S004 tablet
Description: XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XH-S004 placebo tablet
Description: XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
Study: NCT05281523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depemokimab (GSK3511294)
Description: Depemokimab (GSK3511294) will be administered using a pre-filled syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Study: NCT06699407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 bag once, three times a day, 12 months
Study: NCT06698458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: DaRT source will be inserted using endoscopy into the tumor. The sources release by recoil into the tumor short-lived alpha-emitting atoms
Study: NCT06343870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone pellet (100 mg)
Description: Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pellet of cholesterol (placebo)
Study: NCT04590313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: MTPJ I arthrodesis
Study: NCT05491941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sepsis Bundle
Description: Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sepsis Bundle
Description: Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
Study: NCT05211804

Intervention type: DRUG
Intervention: Ophthalmic Drugs
Description: Patients will receive the same treatment as if not a part of the project

Intervention type: DRUG
Intervention: Ophthalmic Drugs
Description: Patients will receive the same treatment as if not a part of the project
Study: NCT05556421

Intervention type: DIAGNOSTIC_TEST
Intervention: uterocervical angle
Description: uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.

Intervention type: DIAGNOSTIC_TEST
Intervention: uterocervical angle
Description: uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
Study: NCT05124509

Intervention type: BIOLOGICAL
Intervention: Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)
Description: Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.

Intervention type: BIOLOGICAL
Intervention: Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
Description: Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
Study: NCT04804631

Intervention type: DEVICE
Intervention: Enteral feeding tubes
Description: Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.

Intervention type: DEVICE
Intervention: Enteral feeding tubes
Description: Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
Study: NCT05963217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-2001
Description: Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Study: NCT04766580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo and nocebo effect
Description: The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and nocebo effect
Description: The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
Study: NCT06352281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
Study: NCT06066554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puva (psoralin and uva )
Description: Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puva (psoralin and uva )
Description: Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puva (psoralin and uva )
Description: Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
Study: NCT04356664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: One or two intramuscular injections of Decapeptyl 3 mg
Study: NCT05798949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic pain rehabilitation: exposure in vivo
Description: Behavioral, chronic pain rehabilitation therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic pain rehabilitation: graded activity
Description: Behavioral, chronic pain rehabilitation therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic pain rehabilitation: acceptance and commitment therapy
Description: Behavioral, chronic pain rehabilitation therapy
Study: NCT05637398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
Study: NCT05769881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided subcostal transversus abdominis plane block
Description: After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound site local anesthetic infiltration
Description: After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
Study: NCT05639153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR30303
Description: DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
Study: NCT05226780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Administered orally
Study: NCT06306963

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Emptying
Description: Measured by radioscintigraphy after overnight fast using a radiolabeled meal consisting of two 99mTc - labeled scrambled eggs, one slice of whole wheat bread and one glass of 111In DTPA skim milk (320kcal, 30% fat). A variable region of interest program will be used to quantitate counts in the stomach. Data will be summarized as GE T1/2 and GE % emptied at 1, 2 and 4 hours.~To assess gastric emptying, the protocol meal as described above will be given. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. Scans will then be done at time 0 subsequently in 15-minute intervals to 90 minutes, then in 30-minute intervals thereafter to 240 minutes supine.
Study: NCT05426902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLE@Duke
Description: SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
Study: NCT06636162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0390
Description: DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.
Study: NCT06408532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: The participants in this group will be switched to IDegLira once daily injection therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed insulin
Description: The participants in this group will be have optimized premixed insulin regimen.
Study: NCT06699355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral administration
Study: NCT06034470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT05024175

Intervention type: DIAGNOSTIC_TEST
Intervention: Disease assessments
Description: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
Study: NCT06034470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given SC
Study: NCT05024175

Intervention type: PROCEDURE
Intervention: Tumor Biopsy
Description: Tumor Biopsy per protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood Test per protocol